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Association between Streptococcus bovis and Colon Cancer
We read with great interest the article by Marcella Beck and
colleagues (1). We fully support their recommendation that
proper distinction between the “Streptococcus bovis” strains
belonging to Streptococcus gallolyticus and Streptococcus infan-
tarius (previously biotypes I and II/2, respectively) should be
made in future studies to obtain a clear picture of the disease
associations of these opportunistic pathogens; above all, be-
cause proper bacterial classification and subsequent recogni-
tion of their association with colon cancer can be a life-saving
event for S. bovis-infected individuals with undiagnosed colon
cancer (4, 5, 8). We were therefore somewhat puzzled by the
authors’ conclusion that the association between S. bovis bac-
teremia and colon cancer (7%) may not be as strong as previ-
ously thought.
Beck and colleagues based their conclusion on the finding
that 3 out of 46 individuals with S. bovis bacteremia presented
with a coincidental colon carcinoma. The authors recognize,
however, that only 15 of these 46 patients underwent full bowel
examination and that in the other patients asymptomatic colon
tumors could be missed. In two cited papers, Ruoff et al. (6)
and Corredoira et al. (2) report respective associations of
100% and 57% for the association of S. bovis biotype I and
colon cancer in patients that underwent colonoscopy. Impor-
tantly, these associations also took into account the presence of
premalignant adenomas that are generally regarded as (early-
stage) precursors of carcinomas. In fact, Corredoira et al. (3)
recently reported that upon examination by colonoscopy, 4
carcinomas and 25 adenomas were detected in 46 S. bovis type
I-infected patients (together, 63%). This confirms the notion
that S. bovis can also associate with (pre)malignant colonic
lesions, which in general do not cause symptoms and cannot be
detected by fecal occult blood tests, and use these as a portal
of entry to cause endocarditis or bacteremia in susceptible
individuals (7, 9). In this view, it was interesting to notice that
Beck and colleagues reported eight additional cases of benign
colon disease which may very well be carcinogenic precursors.
Considering all 21 recorded S. bovis type I bacteremia cases,
this association then would be 33% (5 benign cases/2 carcino-
mas) or 47% assuming that all benign and malignant colon
diseases were detected by colonoscopy (5 benign cases/2 car-
cinomas out of 15 colonoscopies). Both of these numbers fit
within the long line of reports describing a wide range of
associations, with an average of about 40% (1978 to 2008; our
unpublished literature surveys). This wide range can partly be
attributed to the lack of a proper distinction between S. bovis
type I (S. gallolyticus) and type II (S. infantarius) and the fact of
whether or not colonoscopic examination was performed. On
the other hand, it is also likely that these associations can
fluctuate in time and geographical regions, as discussed by
Beck and colleagues.
Taken together, we believe that the association between S.
bovis and colon cancer (defined as carcinomas and premalig-
nant adenomas) should not be underestimated and that full
bowel examination is highly recommendable for patients that
present with S. bovis bacteremia, especially when it concerns S.
gallolyticus subsp. gallolyticus (biotype I).
This letter was Funded by the Dutch Cancer Association (KUN-
2006-3591).
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